Approval of penpulimab-kcqx marks the company’s US regulatory debut and introduces a new immunotherapy option for advanced ...

Invited oral presentation includes in vivo proof-of-concept data for AI-identified targeted therapies to be incorporated into ADCs to treat early-stage lung adenocarcinoma. CAMBRIDGE, MA / ACCESS ...

Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive ...

Summit Therapeutics' partner Akeso received FDA approval for penpulimab-kcqx in NPC, while ivonescimab showed strong data in ...

The intriguing VEGFxPD-1 bispecific antibody space gained oomph with phase III results disclosed April 23 by Akeso Pharmaceuticals Inc. related to Harmoni-6, testing ivonescimab in combination with ...

During a live event, Shannon N. Westin, MD, MPH, and participants discussed their experience treating patients with ...

Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR ...

Researchers from Guilin Medical University and collaborators investigated the potential role of ubiquitin-specific protease 4 (USP4) in the occurrence and development of lung adenocarcinoma.

Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck ...

Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso has won the FDA’s go-ahead for ...